Daiichi Sankyo Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO
DAIICHI SANKYO has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO drugs.
There are three hundred and thirty-four patent family members on DAIICHI SANKYO drugs in forty-seven countries and thirty supplementary protection certificates in eighteen countries.
Summary for Daiichi Sankyo
| International Patents: | 334 |
| US Patents: | 25 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Daiichi Sankyo: | See patent lawsuits for Daiichi Sankyo |
| PTAB Cases with Daiichi Sankyo as patent owner: | See PTAB cases with Daiichi Sankyo as patent owner |
Drugs and US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | Yes | 10,435,404 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 10,730,876 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 9,358,235 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2013235298 | ⤷ Start Trial |
| Canada | 2984910 | ⤷ Start Trial |
| Croatia | P20171384 | ⤷ Start Trial |
| Taiwan | 201706271 | ⤷ Start Trial |
| European Patent Office | 3292122 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | C01405852/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015 |
| 2429524 | CA 2024 00013 | Denmark | ⤷ Start Trial | PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107 |
| 1405852 | 51/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: EDOXABAN, EIN SALZ DAVON ODER EIN SOLVAT DAVON, INSBESONDERE EDOXABANTOSYLAT; REGISTRATION NO/DATE: EU/1/15/993/001-28 20150619 |
| 2429524 | CR 2024 00013 | Denmark | ⤷ Start Trial | PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107 |
| 1405852 | 15C0068 | France | ⤷ Start Trial | PRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
